Nakanishi walked into this quarter priced for perfection after a 17.6% three month run, yet the stock closed at ¥3,245 on the day of the Q2 release with no explosive rerating. The reason lies in the earnings mix. Headline Q2 numbers looked solid on the surface, with revenue of ¥24,745.27m and basic earnings per share of ¥50.14. The tension comes from what that implies relative to a trailing P/E of roughly 120x and thin reported net margins over the past year. Investors are now asking whether this quarter really justifies that degree of valuation stretch.

Is Nakanishi a premium worth paying for at roughly 120x trailing earnings, or are you looking at stretched multiples that current margins cannot support? Compare the stock's current pricing against our valuation analysis for Nakanishi.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: ¥24,745.27m vs. ¥20,646.49m (up about 19.9%)
• Net Income, Q2 2026 vs. Q2 2025: ¥4,163.68m vs. ¥3,069.64m (up about 35.7%)
• Basic EPS, Q2 2026 vs. Q2 2025: ¥50.14 vs. ¥36.74 (up about 36.4%)
• Trailing Twelve Month Net Margin, latest year vs. prior year: 2.5% vs. 6.5% (margin compressed year over year, affected by a one off loss of about ¥13.8b)

Prefer clear charts instead of wading through dense rows of earnings figures and margin ratios? See Nakanishi's full financial picture with a visual breakdown of its valuation in the company report for Nakanishi.

Nakanishi earnings support a measured optimistic view

Nakanishi gives bulls some support here. Revenue and net income both move in the same positive direction year on year, and EPS growth tracks that pattern. That fits a story of a specialist dental and industrial equipment company that can still grow the core business. The recent decision to expand equity based compensation also points to management tying rewards to long term value creation. Together with solid 30 and 90 day share price performance, the latest figures broadly line up with a careful, quality focused growth narrative rather than a short term trading story.

Margin pressure keeps the Nakanishi risk debate alive

There is also clear material for bears. Trailing twelve month net margin compressed from 6.5% to 2.5%, and that includes a sizeable one off loss of about ¥13.8b. Even if that loss does not repeat, it reminds you that profitability is not on a straight line. The stronger Q2 income result helps; yet the full year margin picture still looks fragile. For a company like Nakanishi that sells precision medical and industrial equipment, the key question is whether this margin reset is temporary or becomes the new baseline for returns.

After a margin reset, a 2.5% net margin and a one off loss can be early warning signs. Review the independent risk analysis for Nakanishi which shows 3 important warning signs

Stay Ahead With Simply Wall St

If the mix of strong Q2 earnings and compressed margins has you watching Nakanishi closely, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and wait for a setup that suits you. Once you own Nakanishi or other holdings, use the Portfolio Command Center to cut through noise and focus on the updates that matter to your thesis. For long term conviction, tap into the wisdom of thousands of investors through the Community and test your thinking against different perspectives. This way you can spot potential catalysts and risks early and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Nakanishi Now

Markets move fast and the next breakout stocks rarely stay under the radar for long. Scan fresh ideas before momentum flies and the crowd catches up. Act now.

• Spot potential steady cash generators early by scanning companies in the 18 high quality undervalued stocks while they still look overlooked and prices have not fully caught up.
• Ride the shift toward automation by scouting curated industrial and tech plays in the 36 robotics and automation stocks before strong order books and headlines pull in wider interest.
• Seek resilient portfolio anchors by reviewing the list of solid balance sheet and fundamentals stocks (40 results) before quality balance sheets become the focus and capital rotates toward stronger fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.